PlainMeds drug rankings

Longest Active Drug Shortages

Currently shorted drugs ranked by duration, the longest-running supply disruptions.

Data updated 2026-05-15

35
Drugs ranked
5,366
Top: Atropine
468
Lowest: Meperidine

This board versus the other map

Ustekinumab is NADAC unit-cost #1 of 572 at $26,794.63/unit at FAERS #78 of 524 ≠ Adalimumab FAERS report-volume #1 of 524 at 695,825 at NADAC #8 of 572. Testosterone is a third map: recall-count #1 of 202 (28 actions).

#1
Ustekinumab NADAC
$26,794.63
per unit
#1
Adalimumab FAERS
695,825
reports (not danger)

According to CMS NADAC and FDA FAERS compiled on /methodology. The table below is this board only. Report volume is not per-patient risk, and this page is not medical advice.

What This Ranking Tells Us

Drug shortages occur when demand exceeds supply, typically due to manufacturing problems, raw material shortages, regulatory actions, or business decisions to discontinue low-margin products. The longest shortages tend to involve injectable medications and sterile products that require specialized manufacturing. Chronic shortages force healthcare providers to use alternative therapies, ration supplies, or delay treatments, creating patient safety risks beyond the drug itself.

Top 12 by Days in Shortage

Currently shorted drugs ranked by duration, the longest-running supply disruptions.

Days in Shortage

What this shows atropine leads at 5,366, ahead of fentanyl and epinephrine.

Source FDA Drug Shortage Database

Primary source: FDA Drug Shortage Database. Supplementary labeling: FDA Drug Labels (SPL). These rankings are source-record indexes and do not provide medical, treatment, substitution, or medication-change directions.

Frequently Asked Questions

What causes drug shortages?

The most common causes are manufacturing quality problems (contamination requiring facility shutdowns), supply chain disruptions (raw material unavailability), regulatory actions (FDA inspections finding violations), and market dynamics (manufacturers discontinuing low-profit generics). Injectable sterile products are most vulnerable because few facilities can manufacture them.

What does a shortage ranking measure?

A shortage ranking orders the available FDA shortage records in this catalogue. It reports source-record status and duration; it does not make a treatment, substitution, or procurement recommendation.

Why do some shortages last years?

Long-running shortages typically involve sterile injectable drugs with only 1-2 manufacturers. Resolving manufacturing quality issues can take years of facility upgrades and FDA reinspection. New manufacturers entering the market face 2-4 year FDA approval timelines. The economics of generic injectables often discourage new entrants.

Reading the Longest Active Drug Shortages

This table ranks 35 drugs by days in shortage, sourced from FDA Drug Shortage Database. The current leader is atropine at 5,366, followed by fentanyl and epinephrine. Each row links to a full drug profile so readers can move from headline number to the underlying FDA data, labeling, FAERS reports, recalls, pricing, and shortage status, that explains why a particular drug sits where it does.

Drug shortages occur when demand exceeds supply, typically due to manufacturing problems, raw material shortages, regulatory actions, or business decisions to discontinue low-margin products. The longest shortages tend to involve injectable medications and sterile products that require specialized manufacturing. Chronic shortages force healthcare providers to use alternative therapies, ration supplies, or delay treatments, creating patient safety risks beyond the drug itself.

Rankings are diagnostic, not prescriptive. Absolute numbers are shaped by exposure volume, reporting practices, and data-collection methodology, so a drug near the top is not automatically "worse" than a drug near the bottom, it may simply be older, more widely prescribed, or manufactured by firms with more visible reporting. Context from FDA Drug Shortage Database updates continuously, which means the relative order here can change from one refresh to the next. Rankings on this page are for educational research only and must not be used as a substitute for medical advice from a licensed clinician.

Explore More Rankings

Compare atropine vs fentanyl side-by-side →

These rankings are for informational purposes only and do not constitute medical advice. They copy CMS NADAC and FDA FAERS/Enforcement Report extracts; they do not tell anyone which medicine to take. See methodology and guides.

Source: FDA Drug Shortage Database

See our methodology for how this data is sourced, computed, and verified.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.